↓ Skip to main content

Combination immunotherapy: a road map

Overview of attention for article published in Journal for Immunotherapy of Cancer, February 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#46 of 2,947)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
13 news outlets
blogs
1 blog
twitter
37 tweeters
patent
1 patent
facebook
1 Facebook page
wikipedia
3 Wikipedia pages
googleplus
1 Google+ user

Citations

dimensions_citation
274 Dimensions

Readers on

mendeley
417 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Combination immunotherapy: a road map
Published in
Journal for Immunotherapy of Cancer, February 2017
DOI 10.1186/s40425-017-0218-5
Pubmed ID
Authors

Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton, Jedd D. Wolchok

Abstract

Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent years. However, despite the remarkable clinical efficacy of these agents in a number of malignancies, it has become clear that they are not sufficiently active for many patients. Initial evidence, for example with combined inhibition of PD-1 and CTLA-4 in melanoma and non-small cell lung cancer (NSCLC), has highlighted the potential to further enhance the clinical benefits of monotherapies by combining agents with synergistic mechanisms of action. In order to address the current progress and consider challenges associated with these novel approaches, the Society for Immunotherapy of Cancer (SITC) convened a Combination Immunotherapy Task Force. This Task Force was charged with identifying and prioritizing the most promising prospects for combinatorial approaches as well as addressing the challenges associated with developing these strategies. As a result of the extensive clinical benefit and tolerable side effects demonstrated with agents inhibiting the PD-1 pathway, an overview of current evidence to support its promising potential for use as a backbone in combination strategies is presented. In addition, key issues in the development of these strategies including preclinical modeling, patient safety and toxicity considerations, clinical trial design, and endpoints are also discussed. Overall, the goal of this manuscript is to provide a summary of the current status and potential challenges associated with the development and clinical implementation of these strategies.

Twitter Demographics

The data shown below were collected from the profiles of 37 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 417 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 2 <1%
Belgium 1 <1%
Unknown 414 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 98 24%
Student > Ph. D. Student 60 14%
Other 45 11%
Student > Master 44 11%
Student > Bachelor 43 10%
Other 60 14%
Unknown 67 16%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 83 20%
Medicine and Dentistry 72 17%
Agricultural and Biological Sciences 61 15%
Immunology and Microbiology 48 12%
Pharmacology, Toxicology and Pharmaceutical Science 29 7%
Other 44 11%
Unknown 80 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 135. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2020.
All research outputs
#258,894
of 22,955,959 outputs
Outputs from Journal for Immunotherapy of Cancer
#46
of 2,947 outputs
Outputs of similar age
#6,246
of 310,778 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 27 outputs
Altmetric has tracked 22,955,959 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,947 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,778 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.